BREAST CANCER, HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC Clinical Trials

32 clinical trials for BREAST CANCER, HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC across international registries, including 16 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• AN OPEN-LABEL, MULTI-CENTER, PHASE I/IB STUDY OF IEV407 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER — RECRUITING · PHASE1
• A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS A CDK4/6 INHIBITOR AND LETROZOLE VERSUS PLACEBO PLUS A CDK4/6 INHIBITOR AND LETROZOLE IN PATIENTS WITH ENDOCRINE-SENSITIVE PIK3CA-MUTATED, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER. — RECRUITING · PHASE3
• AN OPEN-LABEL, RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF-07220060 + LETROZOLE VS CDK4/6 INHIBITOR+ LETROZOLE IN PARTICIPANTS>18 YEARS OF AGE WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC TREATMENT. — RECRUITING · PHASE3
• A PHASE 2, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY OF BELZUTIFAN PLUS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER PROGRESSION ON PREVIOUS ENDOCRINE THERAPY (LITESPARK-029) — RECRUITING · PHASE2
• A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF OP-1250 MONOTHERAPY VS STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2- ADVANCED OR METASTATIC BREAST CANCER FOLLOWING ENDOCRINE AND CDK 4/6 INHIBITOR THERAPY (OPERA-01) — RECRUITING · PHASE3
• AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR¿S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY (FOURLIGHT-1) — RECRUITING · PHASE2
• AN OPEN LABEL, RANDOMIZED, MULTICENTER STUDY COMPARING THE EFFICACY AND SAFETY OF THE COMBINATION OF LASOFOXIFENE AND ABEMACICLIB TO THE COMBINATION OF FULVESTRANT AND ABEMACICLIB FOR THE TREATMENT OF PRE- AND POSTMENOPAUSAL WOMEN AND MEN WITH LOCALLY ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER WITH AN ESR1 MUTATION — RECRUITING
• A PHASE 3, OPEN-LABEL, RANDOMIZED, TWO-PART STUDY COMPARING GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AND FULVESTRANT TO STANDARD-OF-CARE THERAPIES IN PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER PREVIOUSLY TREATED WITH A CDK4/6 INHIBITOR IN COMBINATION WITH NON-STEROIDAL AROMATASE INHIBITOR THERAPY (VIKTORIA-1) — RECRUITING · PHASE3
• A PHASE IB/III RANDOMISED STUDY OF CAPIVASERTIB PLUS CDK4/6 INHIBITORS AND FULVESTRANT VERSUS PLACEBO PLUS CDK4/6 INHIBITORS AND FULVESTRANT IN HORMONE RECEPTOR-POSITIVE AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC BREAST CANCER — RECRUITING · PHASE1
• A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF NIVOLUMAB VERSUS PLACEBO IN COMBINATION WITH NEOADJUVANT CHEMOTHERAPY AND ADJUVANT ENDOCRINE THERAPY IN PATIENTS WITH HIGH-RISK, ESTROGEN RECEPTOR-POSITIVE (ER+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) PRIMARY BREAST CANCER — RECRUITING · PHASE3
• "PHASE 3 STUDY OF SACITUZUMAB GOVITECAN (IMMU-132) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH HORMONAL RECEPTOR-POSITIVE (HR+) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) NEGATIVE METASTATIC BREAST CANCER (MBC) WHO HAVE FAILED AT LEAST TWO PRIOR CHEMOTHERAPY REGIMENS." — RECRUITING · PHASE3
• AN OPEN-LABEL RANDOMIZED PHASE 2 TRIAL OF SAR439859, VERSUS ENDOCRINE MONOTHERAPY AS PER PHYSICIAN'S CHOICE IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PRIOR EXPOSURE TO HORMONAL THERAPIES — RECRUITING · PHASE2
• AN ASSESSMENT OF THE BIOLOGICAL AND CLINICAL EFFECTS OF PALBOCICLIB (PD 0332991) WITH OVARIAN SUPPRESSION AND LETROZOLE IN THE NEOADJUVANT TREATMENT OF PATIENTS WITH PREMENOPAUSAL ESTROGEN-RECEPTOR POSITIVE/HER2-NEGATIVE PRIMARY BREAST CANCER — RECRUITING
• SHERBOC: A DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF SERIBANTUMAB PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HEREGULIN POSITIVE (HRG+), HER2 NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR SYSTEMIC THERAPY — RECRUITING · PHASE2
• PALBOCICLIB COLLABORATIVE ADJUVANT STUDY: A RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HORMONE RECEPTOR POSITIVE (HR+) / HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE EARLY BREAST CANCER. — RECRUITING · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF NONSTEROIDAL AROMATASE INHIBITORS (ANASTROZOLE OR LETROZOLE) PLUS LY2835219, A CDK4/6 INHIBITOR, OR PLACEBO IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE LOCOREGIONALLY RECURRENT OR METASTATIC BREAST CANCER WITH NO PRIOR SYSTEMIC THERAPY IN THIS DISEASE SETTING — RECRUITING · PHASE3
• AN OPEN-LABEL, MULTI-CENTER, PHASE I/II STUDY OF ERW316 AS A SINGLE AGENT OR IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH HR+/HER2- BREAST CANCER AND OTHER ADVANCED SOLID TUMORS — COMPLETED · PHASE1
• SERENA-8: A RANDOMISED, MULTICENTRE, OPEN-LABEL, PHASE III STUDY OF CAMIZESTRANT + CAPIVASERTIB VERSUS FULVESTRANT + CAPIVASERTIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE INOPERABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH ONE OR MORE PIK3CA/AKT1/PTEN ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON TREATMENT WITH AN AROMATASE INHIBITOR + CDK4/6 INHIBITOR — COMPLETED · PHASE3
• A PHASE I/II OPEN-LABEL, FIRST-IN-HUMAN, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF OP-1250 MONOTHERAPY IN ADULT SUBJECTS WITH ADVANCED AND/OR METASTATIC HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE BREAST CANCER — NOT_YET_RECRUITING · PHASE1
• A PHASE IB/III STUDY OF IPATASERTIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER — COMPLETED · PHASE1
• A PHASE II, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 400 MG OF RIBOCICLIB IN COMBINATION WITH NON-STEROIDAL AROMATASE INHIBITORS FOR THE TREATMENT OF PRE- AND POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHO RECEIVED NO PRIOR THERAPY FOR ADVANCED DISEASE — COMPLETED · PHASE2
• ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER TRIAL (EMERALD) — COMPLETED · PHASE3
• A MULTINATIONAL, MULTICENTER, PHASE 2 STUDY OF TESETAXEL PLUS A REDUCED DOSE OF CAPECITABINE IN PATIENTS WITH HER2 NEGATIVE, HORMONE RECEPTOR POSITIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE NOT PREVIOUSLY RECEIVED A TAXANE — COMPLETED · PHASE2
• A MULTINATIONAL, MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF TESETAXEL PLUS A REDUCED DOSE OF CAPECITABINE VERSUS CAPECITABINE ALONE IN PATIENTS WITH HER2 NEGATIVE, HORMONE RECEPTOR POSITIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH A TAXANE — COMPLETED · PHASE3
• A PHASE II, MULTICENTER, RANDOMIZED STUDY TO COMPARE THE EFFICACY OF VENETOCLAX PLUS FULVESTRANT VERSUS FULVESTRANT IN WOMEN WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO EXPERIENCED DISEASE RECURRENCE OR PROGRESSION DURING OR AFTER CDK4/6 INHIBITOR THERAPY — COMPLETED · PHASE2
• A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST CANCER OR HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER. — COMPLETED · PHASE3
• A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF GDC-0077 AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE AND TARGETED THERAPIES IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT BREAST CANCER — COMPLETED · PHASE1
• A PHASE III RANDOMIZED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF ALPELISIB IN COMBINATION WITH FULVESTRANT FOR MEN AND POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHICH PROGRESSED ON OR AFTER AROMATASE INHIBITOR (AI) TREATMENT — COMPLETED · PHASE3
• NEOMONARCH: A PHASE 2 NEOADJUVANT TRIAL COMPARING THE BIOLOGICAL EFFECTS OF 2 WEEKS OF ABEMACICLIB (LY2835219) IN COMBINATION WITH ANASTROZOLE TO THOSE OF ABEMACICLIB MONOTHERAPY AND ANASTROZOLE MONOTHERAPY AND EVALUATING THE CLINICAL ACTIVITY AND SAFETY OF A SUBSEQUENT 14 WEEKS OF THERAPY WITH ABEMACICLIB IN COMBINATION WITH ANASTROZOLE IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER — COMPLETED · PHASE2
• A RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF RUXOLITINIB OR PLACEBO IN COMBINATION WITH CAPECITABINE IN SUBJECTS WITH ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER. — NOT_YET_RECRUITING · PHASE2
• A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LEE011 OR PLACEBO IN COMBINATION WITH TAMOXIFEN AND GOSERELIN OR A NON-STEROIDAL AROMATASE INHIBITOR (NSAI) AND GOSERELIN FOR THE TREATMENT OF PREMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER — COMPLETED · PHASE3
• MONARCH 2: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF FULVESTRANT WITH OR WITHOUT LY2835219, A CDK4/6 INHIBITOR, FOR WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER. — COMPLETED · PHASE3

Refine this search